UC Davis/NIH NeuroMab Facility-Administrative Supplement

加州大学戴维斯分校/NIH NeuroMab 设施-行政补充

• 批准号: 9138371
• 负责人: James S Trimmer
• 金额: $ 6.04万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-18 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9138371
• 关键词: Address; Administrative Supplement; Adult; Antibodies; Antigens; Area; Base Sequence; Biochemical; Biological Assay; Brain; California; Cataloging; Catalogs; Cells; Communities; Contractor; DNA Sequence; Data; Diagnostic Procedure; Disabled Persons; Ensure; Funding; Funding Agency; Future; Generations; Genome; Human; Hybridomas; Immunization; Immunoglobulin G; Immunoglobulins; Income; Income Distributions; Institution; Laboratory Research; Learning; Licensing; Link; Literature; Membrane Proteins; Methodology; Mining; Mission; Monoclonal Antibodies; Monoclonal Antibody R24; Mus; National Institute of Neurological Disorders and Stroke; Neurosciences; Neurosciences Research; Nucleic acid sequencing; Peer Review; Play; Price; Productivity; Protein Biochemistry; Proteins; Protocols documentation; Publications; Reagent; Recombinants; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Running; Savings; Seeds; Source; Specificity; Synthetic Vaccines; Therapeutic; Time; United States National Institutes of Health; Universities; Vial device; Work; aged; base; cost; design; experience; flexibility; handicapping condition; mammalian genome; nervous system disorder; novel; programs; protein function; public health relevance; receptor; research and development

 DESCRIPTION (provided by applicant): The availability of high-quality, reliable and monospecific mouse monoclonal antibodies (mAbs) that have been validated and optimized for use in mammalian brain (i.e. NeuroMabs) is of utmost importance to many areas of neuroscience research. Having such reagents for each of the proteins expressed in the brain is necessary to undertake biochemical and immunohistochemical studies to begin to link the nucleic acid sequence information derived from genome-based approaches to the function of the encoded gene products in the brain. Unfortunately, the lack of antibodies against a particular gene product, or antibodies that lack specificity, can severely handicap an entire subfield of neuroscience research and thereby impede progress towards understanding the mechanisms that underlie neurological disease. The UC Davis/NIH NeuroMab Facility works towards this unmet need in two major ways: by generating NeuroMabs for targets that are deemed high-priority by NIH and by distributing them on a low-cost non-profit basis to the neuroscience research community. Seed funds from UC Davis and various NIH sources allowed for the creation of our Facility in 2005 and, over the past nine years, we have undertaken mAb projects against over 400 brain proteins and generated a catalog of over 370 NeuroMabs. Through our contractor Antibodies Incorporated (AI), we have distributed over 44,500 vials of NeuroMabs at low cost to hundreds of researchers at a multitude of different institutions worldwide and our end users have cited the use of NeuroMabs in over 1500 original research publications. Assuming a conservative for-profit price of $350 per 100 µg vial of purified mAb, an estimate of the NeuroMab non-profit savings to end users and their respective funding agencies is over $12.5 million. We have proven ourselves to be an establishment with a strong track record of important contributions and we wish to continue serving neuroscience researchers as best as we can. The worthiness of our Facility to the NIH and its mission has been demonstrated time and again through various funding initiatives over the years, most recently from the NIH Director's Transformative R01 Program. In addition, the combined support and cooperation of the NIH, the Regents of the University of California and AI have enabled us since 2011 to collect program income from the distribution of NeuroMabs to support future Facility self-sufficiency and new mAb research and development. However, the combination of the Transformative R01 funds and the accumulated program income is insufficient to hold onto our experienced senior staff, to keep the Facility running at its present-day level of productivity and to continue doing projects of high priority to NINDS. Maintaining strong support from NIH through additional R24 funding would be instrumental to retaining our valuable human and technological resources, preserving our current UC Davis infrastructure and keeping intact our exceptional protection from royalty and licensing surcharges that would unnecessarily raise the prices of NeuroMabs for our end users.

 描述（由申请人提供）：高质量、可靠且单特异性的小鼠单克隆抗体 (mAb) 已经过验证和优化，可用于哺乳动物大脑（即 NeuroMab），这对于神经科学研究的许多领域至关重要。针对大脑中表达的每种蛋白质的此类试剂对于进行生化和免疫组织化学研究是必要的，以开始将基于基因组的方法获得的核酸序列信息与编码的功能联系起来。不幸的是，缺乏针对特定基因产物的抗体，或缺乏特异性的抗体，可能会严重阻碍神经科学研究的整个子领域，从而阻碍对神经系统疾病机制的理解。 NIH NeuroMab 设施主要通过两种方式来满足这一未满足的需求：针对 NIH 认为高度优先的目标生成 NeuroMab，并以低成本非营​​利的方式将其分发给神经科学研究界。加州大学戴维斯分校和 NIH 的各种资金支持我们于 2005 年建立了该设施，在过去的九年里，我们针对 400 多种脑蛋白开展了单克隆抗体项目，并通过我们的承包商 Antibodies Incorporated 生成了超过 370 种 NeuroMab 的目录。 AI），我们以低成本向全球多个不同机构的数百名研究人员分发了超过 44,500 瓶 NeuroMab，我们的最终用户引用了 NeuroMab 在假设每 100 µg 小瓶纯化 mAb 的保守营利价格为 350 美元，NeuroMab 非营利组织为最终用户及其各自的资助机构节省的费用估计超过 1250 万美元。是一个在重要贡献方面拥有良好记录的机构，我们希望继续尽我们所能为神经科学研究人员提供服务。我们的设施对 NIH 及其使命的价值已经得到时间和证明。多年来，我们再次通过各种资助计划，最近一次来自 NIH 院长的变革性 R01 计划。此外，NIH、加州大学董事会和 AI 的共同支持与合作使我们自 2011 年以来能够从该计划中收取计划收入。分配 NeuroMab 以支持未来设施自给自足和新的单克隆抗体研究和开发。然而，变革性 R01 资金和累计项目收入的结合不足以留住我们经验丰富的高级员工，以保持设施以目前的生产力水平运行并继续开展 NINDS 高度优先的项目，通过额外的 R24 资金维持 NIH 的大力支持将有助于保留我们宝贵的人力和技术资源，保护我们当前的加州大学戴维斯分校基础设施并保持。我们对特许权使用费和许可附加费的特殊保护完好无损，这些费用会不必要地提高我们最终用户的 NeuroMab 价格。